[1] World Health Organization. WHO report 2013: Global tuberculosis report 2013. WHO/HTM/TB/2013.11[R/OL]. Geneva:World Health Organization,2013[2013-11-25]. http://www.who.int/tb/publications/global_report/en/index.html. [2] Harrison C. Vaccines: Protecting against tuberculosis. Nat Rev Drug Discov, 2011, 10(11):813. [3] Aagaard C, Hoang T, Dietrich J, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med, 2011, 17(2): 189-194. [4] Spies FS, da Silva PE, Ribeiro MO, et al. Identification of mutations related to streptomycin resistance in clinical isolates of Mycobacterium tuberculosis and possible involvement of efflux mechanism. Antimicrob Agents Chemother, 2008, 52(8):2947-2949. [5] Cuevas-Córdoba B, Cuellar-Sánchez A, Pasissi-Crivelli A, et al. rrs and rpsL mutations in streptomycin-resistant isolates of Mycobacterium tuberculosis from Mexico. J Microbiol Immunol Infect,2013, 46(1):30-34. [6] Ulger M, Aslan G, Emekda G, et al. Investigation of rpsL and rrs gene region mutations in streptomycin resistant Mycobacterium tuberculosis complex isolates. Mikrobiyol Bul(Turkish), 2009, 43(1):115-120. [7] Wong SY, Lee JS, Kwak HK, et al. Mutations in gidB confer low-level streptomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2011, 55(6):2515-2522. [8] 杜长梅, 王国斌, 徐吉英, 等. 河南省第二轮结核病耐药监测及耐药趋势研究. 中国防痨杂志, 2006,28(2): 95-100. [9] 刘宇红,姜广路,赵立平,等.第四次全国结核病流行病学抽样调查——结核分枝杆菌耐药性分析与评价.中华结核和呼吸杂志, 2002,25(4): 224-227. [10] 李国明, 吴兴荣, 张缇, 等.湖北省结核分枝杆菌耐药性监测研究.中华结核和呼吸杂志, 2002, 25(12): 723-727. [11] 杨芳玲,王文君,孟炜,等.新疆克拉玛依市耐药结核病流行状况分析.中国防痨杂志,2008,30(3):228-229. [12] Wrold Health Oranization. Anti-tuberculosis drug resistance in the world:Fourth global report. WHO/HTM/TB/2008394[R/OL]. Geneva:World Health Organization,2008[2013-03-11]. http://whqlibdoc.who.int/hq/2008/WHO_HTM_TB_2008394_eng.pdf. |